Skip to content Skip to footer
Subscribe Now
Johnson & Johnson
NEWS

Johnson & Johnson Receives the EC’s Approval for Darzalex Regimen to Treat Newly Diagnosed Multiple Myeloma (NDMM)

Shots: The EC has approved Darzalex (SC) + bortezomib, lenalidomide & dexamethasone (D-VRd) to treat NDMM pts; sBLA under the US FDA’s review Approval was based on P-III (CEPHEUS) trial assessing D-VRd (n=197) vs VRd (n=198) in 395 ASCT-ineligible or deferred pts, in 13 countries across the EU, North & South America At 59mos. mFU, trial…
April 8, 2025

Read more

Viewpoints_Yelak Biru
VIEWPOINTS

Fund Raising Initiative: Yelak Biru from International Myeloma Foundation in Conversation with PharmaShots

Shots:   As a fund-raising initiative, the International Myeloma Foundation began a 3-day, 2-night cycling expedition from Aug 29thto Sep 3rd  The initiative supports patient education, advocacy, and next-gen research to advance a cure for multiple myeloma  Today, at PharmaShots we have Yelak Biru, President and CEO of the International Myeloma Foundation, shedding light on this…
October 16, 2024

Read more

Exclusive_Chris Heery_2024
EXCLUSIVE

Advancing Care for Hematologic Malignancies: Chris Heery from Arcellx in a Stimulating Dialogue Exchange with PharmaShots

Shots:  Arcellx’s Anito-cel, a BCMA CAR-T therapy recently got the FTD, ODD, RMAT designations by the FDA for the treatment of patients with relapsed or refractory multiple myeloma (r/rMM)  Today, at PharmaShots we have Chris Heery, Chief Medical Officer at Arcellx, shedding light on Anito-Cel therapy in advancing care for multiple myeloma  In late 2022,…
September 30, 2024

Read more

Viewpoints_Dr. Robert Rifikin
VIEWPOINTS

Establishing Safe Treatment: Dr. Robert Rifikin from Rocky Mountain Cancer Centers in Conversation with PharmaShots

Shots:  There is an average lifetime risk of getting multiple myeloma of about 1 in 103 men and 1 in 131 women in the United States  Treatment of multiple myeloma using fourth-line therapy like teclistamab can induce issues like cytokine release syndrome (CRS) and neurotoxicity   Today, at PharmaShots we have Dr. Robert Rifikin from Rocky…
August 5, 2024

Read more

New Drug Designations - August 2023
INSIGHTS+

New Drug Designations – August 2023

Shots:  PharmaShots' designation report provides a concise overview of several drugs and their designations by the US FDA, the EU, Japan, and China. This month’s report includes 8 biological drugs, 13 small molecules, 4 cell and gene therapies, 3 diagnostic tests and 5 devices  Genprex’ Reqorsa, focused on the treatment of SCLC, is the drug to receive ODD…
September 18, 2023

Read more

Viewpoints_Tania Small
VIEWPOINTS

Tania Small, VP, Global Medical Oncology Head, GSK, Shares Insights on Target the Future Think Tank Challenge

Shots: Tania spoke about the Target the Future Think Tank Challenge and how it will advance and address key needs in the multiple myeloma  She also talked about GSK’s collaboration with the HealthTree Foundation to provide access, education, and support for underserved communities of multiple myeloma The interview gives a profound understanding of how GSK…
September 14, 2022

Read more

Load more